Docetaxel: In hormone-refractory metastatic prostate cancer

Drugs

Volumn 65, Issue 16, 2005, Pages 2287-2294

  McKeage, Kate ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DOCETAXEL; ESTRAMUSTINE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITONAVIR; THALIDOMIDE; WARFARIN;

ALOPECIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HUMAN; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CARCINOMA; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL; TASTE DISORDER; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 27644539039     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565160-00003     Document Type: Review

References (36)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55 (1): 10-30
2. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-20
3. de Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. Eur J Cancer 2005 Mar; 41 (4): 502-7
4. Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004 Dec 15; 10 (24): 8147-51
5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756-64
6. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refactory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999; 17: 2506-13
7. Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 2004; 24: 2897-903
8. Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003 Nov; 170 (5): 1709-16
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: the TAX 327 Investigators. N Engl J Med 2004; 351 (15): 1502-12
10. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13 (10): 2643-55
11. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26 (5 Suppl. 17): 3-7
12. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001; 28 (4 Suppl. 15): 3-7
13. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991; 83: 288-91
14. Díaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55
15. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56 (6): 1253-5
16. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52 (24): 6940-4
17. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57 (2): 229-33
18. Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 2001; 57 (2): 366-70
19. Li Y, Hong X, Hussain M, et al. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 2005; 4 (3): 389-98
20. Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate 2000; 44 (4): 275-8
21. Fischel J-L, Ferrero J-M, Formento P, et al. Taxotere-5′-deoxy-5- fluorouridine combination on hormone-refractory human prostate cancer cells. Anti-Cancer Drugs 2005; 16 (3): 309-16
22. Huang SF, Kim S-J, Lee AT, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res 2002; 62 (20): 5720-6
23. Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol 2005 Mar; 26 (3): 623-8
24. Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anti-Cancer Drugs 2004; 15 (2): 161-7
25. Tolcher AW, Kuhn J, Schwartz G, et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004 Aug 1; 10 (5): 5048-57
26. Aventis Pharmaceuticals Inc. Taxotere® (docetaxel) injection concentrate: prescribing information. 2005 [online]. Available from URL: http://www.aventis-us.com [Accessed 2005 Aug 9]
27. Van Veldhuizen PJ, Reed G, Aggarwal A, et al. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98 (9): 1855-62
28. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64 (20): 7426-31
29. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1 (3): 277-99
30. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22 (13): 2532-9
31. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. The Cancer and Leukemia Group B. Cancer 2003; 98 (12): 2592-8
32. Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11 (10): 3854-61
33. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21 (1): 123-8
34. Goodin S, Rao KV, Kane M, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005; 56 (2): 199-204
35. European Medicines Agency. European Medicines Agency: Committee for Medicinal Products for Human Use, 13-16 September 2004 [media release; online]. Available from URL: http://www.emea.eu.int [Accessed 2005 Aug 28]
36. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - v.2.2005: prostate cancer. 2005 Jul 26 [online]. Available from URL: http://www.nccn.org [Accessed 2005 Aug 29]